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Abstract
Objectives: Norovirus infections pose great economic and
disease burden to health systems around the world. This
study quantifies the investments in norovirus research
awarded to UK institutions over a 14-year time period.
Design: A systematic analysis of public and philanthropic
infectious disease research investments awarded to UK
institutions between 1997 and 2010.
Participants: None
Setting: UK institutions carrying out infectious disease
research.
Main outcome measures: Total funding for infectious disease
research, total funding for norovirus research, position of
norovirus research along the R&D value chain.
Results: The total dataset consisted of 6165 studies with sum
funding of £2.6 billion. Twelve norovirus studies were iden-
tified with a total funding of £5.1 million, 0.2% of the total
dataset. Of these, eight were categorized as pre-clinical,
three as intervention studies and one as implementation
research. Median funding was £200,620.
Conclusions: Research funding for norovirus infections in
the UK appears to be unacceptably low, given the burden
of disease and disability produced by these infections.
There is a clear need for new research initiatives along
the R&D value chain: from pre-clinical through to imple-
mentation research, including trials to assess cost-effective-
ness of infection control policies as well as clinical, public
health and environmental interventions in hospitals, con-
gregate settings and in the community.
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Introduction
Norovirus is reportedly the most common enteric
pathogen and a major cause of short-term illness in
the UK.1 Although norovirus infections, which cause
vomiting and diarrhoea, are short-term and mostly
self-limiting with symptoms that typically resolve
within three or four days, they create much burden
on the National Health System (NHS) in the UK.
With a low infectious dose and short-lived immunity,
faecal–oral transmission of norovirus is common.
Outbreaks of norovirus infections, which can occur
in almost any environment, including congregate set-
tings such as hospital wards, cruise ships, schools and
prisons, and typically occur during the winter months,
are particularly diﬃcult for healthcare services to deal
with and may attract much media attention. Oysters
are the vehicle for approximately 85%of norovirus (or
suspected norovirus) outbreaks related to food.1
Outbreaks in England are reported through the
Hospital Outbreak Reporting Scheme and collated
by Public Health England. Norovirus has been
reported as being the most common enteric pathogen
in the UK, with an incidence rate of 47 community
cases per 1000 person-years and 2.1 general practi-
tioner consultations per 1000 person-years,2 though
the annual incidence of norovirus is unpredictable.
For example, there was a 39% reduction in reported
norovirus outbreaks for the July 2010 to June 2011
season compared with the previous season (with a
similar pattern in the laboratory reporting).1
However, across the winter of 2012–2013, the
number of reported norovirus infections increased
compared to 2011–2012 ﬁgures, owing in part to a
novel dominant circulating strain and an earlier
start to the norovirus ‘season’.3
In the UK national media, there has been wide
coverage of these outbreaks which led to closure of
hospital wards in the UK.4 There has also been wide
UK media coverage of the increased incidence of
norovirus infections in the United States of America
(USA).5 The economic burden on the NHS of noro-
virus infections is signiﬁcant, with an estimated cost
to the NHS of around £100 million each year.6
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According to the 2010 Global Burden of Disease
Study, diarrhoeal illnesses account for the fourth
greatest disease burden globally (as measured in
disability-adjusted life-years) across all communic-
able and non-communicable diseases.7 However,
there are no global estimates speciﬁcally on the dis-
ease burden of norovirus. This is thought to be for
several reasons, including the diﬃcult detection of the
virus owing to an inability for propagation in cell
culture, local genetic variations that complicates the
use of commonly employed detection assays, limited
reporting to health oﬃcials because of the acute and
short-lasting nature of the disease, and a lack of
standardization of diagnostic and surveillance pro-
grammes between countries.8
Reports from the surveillance systems of selected
countries suggest that norovirus is likely to be high
burden worldwide. There are an estimated 20.9 mil-
lion cases annually in the USA.9 In Australia, noro-
virus infections were considered to be responsible for
almost 80% of the non-foodborne outbreaks where
the pathogen could be identiﬁed.10 There are indica-
tions that the pathogens responsible for acute infec-
tious diarrhoea can be responsible for the
development of chronic gastrointestinal disorders.11
We report here the research investments awarded
to UK institutions on norovirus research, as part of
the Research Investments in Global Health (ResIn)
project.12
Methods
The UK research institutions have been awarded
around £2.6 billion of public and charitable funds
to carry out infectious disease research over the 14-
year period from 1997 to 2010.13 For the original
study, we systematically collated and analysed data
on research awards from all the major funders of
biomedical research, including the Medical
Research Council, Wellcome Trust, Department of
Health (and the National Institute of Health
Research), other government departments, Bill and
Melinda Gates Foundation, the European
Commission and other charities that fund research.
We included in our analysis all studies related to
human infectious disease (including zoonoses),
where the funding was awarded to a UK institution
between 1997 and 2010. The ﬁnal dataset contained
information on 6170 studies, and these were categor-
ized by several disease areas, themes and speciﬁc
pathogens, and by type of science along the R&D
value chain (pre-clinical, phase I–III trials, phase IV
and intervention studies, implementation and oper-
ational research). No private sector funding was
included in this analysis as the publicly available
data are very limited from these sources and were
considered to be under-representative. We excluded
unfunded studies. We also excluded studies where
funding was awarded to a non-UK institution that
had UK partners. Analysis was carried out in
Microsoft Excel and Access (versions 2000 and
2007) and Stata (version 11).
Results
We identiﬁed just 12 infectious disease studies that
were speciﬁcally related to norovirus research
(Table 1), of which eight were categorized as pre-
clinical, three as intervention studies and one as
implementation research. The total funding for
these 12 studies was £5.1 million (0.2% of total
funding for infectious disease research in the study
period), with mean funding per study of £425,188
(standard deviation £568372) and median funding
of £200,620 (inter-quartile range £91362-435731).
Nine studies were university-led (three by Imperial
College London), one small study was led by a
National Health Service Hospital Trust in England
(with funding of just £684) and two were led by the
Health Protection Agency (HPA, now Public Health
England) and the Department for Environment,
Food and Rural Aﬀairs. The Wellcome Trust
funded ﬁve studies (total investment of £2.4 million),
European Commission three studies (£2.1 million),
the MRC two studies (£506,871) and the
Department of Health one study (£93,570). The
funding source for the ﬁnal study, which received
£684 for a nosocomial hospital-based study, was
identiﬁed as coming from the researchers undertak-
ing the study or another local source. There is no
clear temporal trend in awards (Figure 1).
By comparison, over the study period, other
enteric pathogens received far greater levels of
investment, such as Salmonella (145 studies, total
investments of £55.7 million) and Campylobacter
(87 studies, £24.1 million). Investment for rota-
virus-related research was £5.8 million across 18
studies.
The US National Institutes of Health has an
online searchable database that documents their
research investments. We searched this Reporter
database, using ‘norovirus’ as a keyword for studies
funded between 1997 and 2013.14 The database query
used this keyword to search project titles, abstracts
and project terms associated with the studies. This
search produced 275 awards with total investment
of $127 million (mean funding per study $460,130,
median funding $282,151, average total annual fund-
ing $7.4 million). All the identiﬁed studies were
awarded to US-based institutions. We did not
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systematically categorize the quantity of each type of
research that may be included along each part of the
R&D value chain.
Discussion
Statement of principal findings
This study investigated norovirus research invest-
ments awarded to UK institutions between 1997
and 2010. Twelve norovirus studies were identiﬁed
with a total funding of £5.1 million, 0.2% of the
total dataset of all infectious disease research (6165
studies, sum funding of £2.6 billion). Of these, eight
were categorized as pre-clinical, three as intervention
studies and one as implementation research. Median
funding was £200,620. This appears to be unaccept-
ably low, given the burden of disease and disability of
norovirus infections, and there a clear need for new
research initiatives and prioritising by the funders.
Strengths and weaknesses of the study
Our analysis systematically describes infectious disease
research funding awarded to UK institutions and spe-
ciﬁcally here the investments in norovirus research, and
this is the ﬁrst time such an analysis has been carried out
in the UK. Mapping the funding landscape in this
manner can allow funders and policymakers to learn
how best to invest their limited resources in order to
lead to optimal outputs and health outcomes both in
theUKand globally. It promotes transparency and can
help to reduce duplication of investments between local
and international funders.
Our study has several limitations, which are dis-
cussed more fully elsewhere.13 These include a lack
of private sector funding, which has particular
implications in areas such as vaccine development
and diagnostics. Another limitation arises because it
is diﬃcult to assess associations with other areas of
research that are not directly about norovirus, but
which nonetheless have an impact, such as preventive
measures relating to enteric diseases generally. We rely
on the original data being accurate, no attempt was
made to investigate any contribution of indirect and
estate costs (including the introduction of full eco-
nomic costing formulae in the UK), and we do not
know how much money was forwarded to any colla-
borating partners. Creation of disease categories and
allocation of studies to the categories is subjective.
Strengths and weaknesses in relation
to other studies, discussing particularly
any differences in results
There is no systematic analysis available globally
for norovirus research, and thus we cannot undertake
an international comparison. The G-FINDER15 ana-
lysis by Policy Cures collect research data on neg-
lected diseases, but this does not include norovirus.
Meaning of the study: possible implications for
clinicians or policymakers
Institutions funding infectious disease research have
not explicitly prioritized norovirus-related studies.
There are challenges to pre-clinical norovirus-related
research due to a lack of animal models and lack of a
cell culture system.8 Consequently, the knowledge
relating to the pathogenesis of existing and emerging
strains with increased virulence is limited. It appears as
though the US National Institute for Health has made
proportionately greater investment in norovirus than
that received by UK institutions. This highlights how
information on global funding of norovirus-related
research is critical in order to identify funding gaps,
better prioritise funding, and to help identify countries
and institutions with strengths in norovirus-related
research in pre-clinical work, clinical trials, interven-
tion studies or operational research.
Unanswered questions and future research
Research investment is needed to develop new tech-
niques for pre-clinical research and to employ recent
technological advances in studies of viruses, including
in gene sequencing. Furthermore, research funding is
needed for intervention studies and implementation
research to identify which infection control policies
and clinical interventions as well as public health and
environmental measures help to eﬀectively address
norovirus outbreaks. Global incidence and
Figure 1. Breakdown of investment in norovirus
research by funder over time.
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prevalence data are needed to better estimate the
burden of disease and disability due to norovirus so
that pathogen speciﬁc burden estimates can be devel-
oped by the Global Burden of Disease studies.
Conclusions
Research funding for norovirus infections appears to be
unacceptably low, given the burden of disease and dis-
ability produced by these infections. There is a clear need
for new research initiatives along the R&D value
chain: from pre-clinical through to implementation
research, including trials to assess cost-eﬀectiveness of
infection control policies as well as clinical, public
health and environmental interventions inhospitals, con-
gregate settings and in the community. Investment is
needed to develop animal models and diagnostics tests
to better characterise norovirus strains and investment in
surveillance to better estimate disease burden in order to
better target and prioritise future research funding.
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